Boston Sci, St. Jude Face New Federal Inquiries From OIG, DOJ
This article was originally published in The Gray Sheet
Executive Summary
The two firms’ cardiac devices businesses are facing more scrutiny from the federal government. Boston Scientific is facing an inquiry from the HHS Office of Inspector General, and St. Jude from the Department of Justice.
You may also be interested in...
Boston Scientific CRM In 2010: Steep Challenges, Some Prospects
Sales force firings and perceived product design issues are adding to an already challenging cardiac rhythm management picture for Boston Scientific in 2010
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.